Endeavor BioMedicines Announces Appointment of Chris Krueger, J.D., as Chief Operating Officer
Published
SAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the appointment of Chris Krueger, J.D., as Chief Operating Officer (COO). Mr. Krueger brings extensive experience from the life sciences industry that will be instrumental to Endeavor's continued growth and success. “Chris is an extremely accomplishe
Full Article